HK Stock Market Move | GRAND PHARMA (00512) rose nearly 5% as the international multicenter Phase III study of CBT-001 met its primary clinical endpoint, significantly controlling pterygium lesions.

GRAND PHARMA (00512) rose nearly 5%, up 4.2% as of press time to HK$4.465, with a turnover of HK$7.1222 million. On the news front, on November 5, GRAND PHARMA issued an announcement that the international multicenter Phase III clinical trial of the company's globally innovative ophthalmic drug CBT-001 (GPN00153) met its primary clinical endpoint, and CBT-001 has been proven capable of altering the disease course of pterygium. This means that CBT-001 is the world's first drug to demonstrate a therapeutic effect on pterygium through statistically significant improvement in hyperemia and lesion size, and is expected to fill the treatment gap for pterygium in the future, bringing a brand-new option to patients worldwide. It is worth noting that GRAND PHARMA holds the exclusive production (including technology transfer) and commercialization rights for CBT-001 in mainland China, Hong Kong, Macau, and Taiwan. If successfully approved for marketing, CBT-001 will become the first product globally for the treatment of pterygium, which will not only completely change the current clinical treatment landscape for pterygium and bring a brand-new non-surgical treatment option to hundreds of millions of patients, but will also build the company's differentiated competitive advantage in the field of ophthalmic anti-inflammatory and proliferative disease treatment.